Herpes Simplex Virus (HSV) Testing: Laboratory Methods, Sample Types, and Clinical Applications

Herpes simplex virus (HSV) testing is a core laboratory service for confirming infection with HSV-1 and HSV-2, guiding antiviral treatment, and preventing transmission in clinical and public health settings. This technical article explains the available specimen types, assay methods such as PCR and type-specific serology, and the main application scenarios and frequently asked questions related to herpes simplex virus laboratory diagnosis.

Technical Overview

Herpes simplex virus (HSV) is an enveloped, double-stranded DNA virus belonging to the family Herpesviridae. Two antigenically distinct serotypes are clinically relevant: HSV-1, which classically causes orolabial herpes ("cold sores") but is increasingly identified as a cause of genital herpes, and HSV-2, which remains the predominant cause of genital ulcer disease worldwide. Following primary infection, HSV establishes lifelong latency in sensory nerve ganglia and can periodically reactivate, producing recurrent lesions or asymptomatic viral shedding.

The clinical spectrum of HSV infection ranges from mild mucocutaneous lesions to severe, life-threatening disease, including herpes simplex encephalitis (HSE), neonatal herpes, keratitis, and disseminated infection in immunocompromised patients. Because clinical presentation alone is unreliable—many infections are atypical or asymptomatic—laboratory confirmation is essential for accurate diagnosis, typing, treatment decisions, and patient counseling.

Herpes simplex virus examination relies on two complementary laboratory strategies: direct detection of the virus or its genetic material in clinical specimens (nucleic acid amplification testing, culture, antigen detection) and indirect detection of the host immune response through type-specific antibody serology. Accredited third-party laboratories and clinical microbiology laboratories typically operate under quality management frameworks such as ISO 15189 for medical laboratories, with method performance aligned to internationally recognized clinical laboratory guidelines.

Testing Samples

Lesion and Vesicle Swabs

Swabs taken from intact vesicles, ulcers, or mucocutaneous lesions are the primary specimens for direct viral detection. Vesicle fluid and the base of freshly opened lesions yield the highest viral loads. Specimens should be collected using synthetic (nylon or polyester) swabs and placed in viral transport medium or a dry transport system, then stored refrigerated at 2–8 °C and tested promptly to preserve nucleic acid integrity.

Cerebrospinal Fluid (CSF)

CSF is the critical specimen for suspected herpes simplex encephalitis or aseptic meningitis. Molecular detection of HSV DNA in CSF is the diagnostic reference method for central nervous system infection, and CSF PCR has largely replaced brain biopsy in this context.

Blood and Serum

Serum or plasma is used for type-specific antibody testing (HSV-1 IgG and HSV-2 IgG). Whole blood, EDTA plasma, and buffy coat specimens may also be tested by PCR in selected scenarios such as suspected disseminated neonatal disease or infection in severely immunocompromised patients.

Neonatal and Ocular Specimens

For evaluation of neonatal herpes, combined surface swabs (conjunctival, oropharyngeal, and rectal), CSF, and blood are typically collected as a diagnostic panel. For ocular disease, corneal or conjunctival scrapings and tear samples support the diagnosis of HSV keratitis.

Mucosal Swabs for Asymptomatic Shedding

Genital or oral swabs collected in the absence of symptoms can detect asymptomatic viral shedding, which is epidemiologically important for transmission counseling and for research and antiviral suppression studies.

Testing Items

Standard herpes simplex virus examination panels generally include the following analytes:

• HSV-1 DNA detection (qualitative and quantitative real-time PCR)
• HSV-2 DNA detection (qualitative and quantitative real-time PCR)
• Combined HSV-1/HSV-2 DNA screening with type-differentiating assays
• HSV-1 IgG type-specific antibody (based on glycoprotein G-1 antigen)
• HSV-2 IgG type-specific antibody (based on glycoprotein G-2 antigen)
• HSV IgM antibody testing, with cautious clinical interpretation
• HSV antigen detection by direct immunofluorescence on lesion material
• Virus isolation and identification by cell culture with confirmatory staining
• HSV PCR panels integrated into meningitis/encephalitis and sexually transmitted infection (STI) multiplex workflows

Testing Methods

Nucleic Acid Amplification Testing (NAAT / Real-Time PCR)

Polymerase chain reaction is the current reference standard for detecting HSV in lesions, mucocutaneous sites, CSF, and neonatal specimens. Assays target conserved genomic regions such as the glycoprotein B (gB), DNA polymerase (UL30), or thymidine kinase genes. Real-time PCR with type-specific probes simultaneously detects and differentiates HSV-1 and HSV-2 with high analytical sensitivity and specificity, typically delivering results within a few hours. Quantitative formats allow viral load monitoring in research and selected clinical contexts.

Type-Specific Serology

Modern IgG assays use type-specific antigens derived from glycoprotein G (gG-1 and gG-2), which overcome the extensive cross-reactivity of older whole-virus antigen assays and enable reliable distinction between HSV-1 and HSV-2 past infection. IgG seroconversion generally occurs between two weeks and three to four months after exposure, so a negative result during the early window period warrants repeat testing. IgM testing has limited diagnostic value because IgM can reappear during reactivation and may cross-react, so it is not recommended as a standalone marker of recent infection. Immunoblotting remains a confirmatory reference method for equivocal or low-index results.

Viral Culture and Shell Vial Assay

Direct Fluorescent Antibody (DFA) Testing

DFA detects viral antigens in cells collected from lesion bases using fluorescein-labeled type-specific monoclonal antibodies. It offers rapid turnaround (under a few hours) and direct typing capability, but its sensitivity is inferior to PCR and depends heavily on adequate cell collection and specimen quality.

Cytology (Tzanck Smear)

Microscopic examination of lesion scrapings can reveal multinucleated giant cells and inclusion bodies suggestive of herpesvirus infection. The method is rapid and inexpensive but cannot differentiate HSV types, varicella-zoster virus, or definitively confirm the diagnosis, and is therefore considered only an adjunct screening tool.

Laboratories performing these assays apply documented quality assurance measures, including internal amplification controls, external quality assessment participation, and validation of analytical sensitivity, specificity, and turnaround performance consistent with ISO 15189 requirements and internationally recognized clinical microbiology guidance.

Applications

Herpes simplex virus examination supports a wide range of clinical and public health applications:

• Confirmation of genital ulcer disease and incorporation into comprehensive STI screening panels alongside HIV, syphilis, and other pathogens
• Etiological diagnosis of herpes simplex encephalitis and aseptic meningitis through CSF PCR, enabling prompt antiviral therapy
• Neonatal herpes evaluation, including diagnostic workup of exposed newborns and maternal testing near delivery to guide delivery-mode decisions
• Pregnancy management and preconception screening to reduce mother-to-child transmission risk
• Diagnosis and follow-up of HSV keratitis and other ocular herpes manifestations
• Assessment of immunocompromised patients, including transplant candidates and recipients, where HSV reactivation can cause severe or disseminated disease
• Partner testing, transmission-risk counseling, and evaluation of asymptomatic individuals with known exposure
• Epidemiological surveillance, vaccine research, and evaluation of antiviral suppression regimens through shedding-rate and viral-load studies

FAQ

Q: What is the preferred test for an active herpes lesion?

A: Real-time PCR on a swab of the lesion is the recommended first-line test because of its superior sensitivity, rapid turnaround, and ability to differentiate HSV-1 from HSV-2. Testing early in the course of the lesion, ideally during the vesicle or early ulcer stage, maximizes detection rates.

Q: How long after exposure can antibodies be detected?

A: Type-specific IgG antibodies typically develop within two weeks to three months after infection, and some individuals seroconvert more slowly. If initial IgG testing is negative but clinical suspicion persists, repeat testing after the window period is advised.

Q: Does a positive HSV IgM mean a new infection?

A: Not reliably. HSV IgM may appear during primary infection but can also be present during reactivation or recur with subsequent episodes. IgG-based testing, including seroconversion documented on paired specimens, is the preferred approach for assessing infection status.

Q: What does a positive HSV-2 IgG result without symptoms mean?

A: It indicates prior infection with HSV-2. Most HSV-2 infections are unrecognized or asymptomatic, and such individuals can still shed virus transmissibly. Confirmatory testing may be considered for low-index results, followed by medical consultation regarding management and partner notification.

Q: Can herpes simplex virus testing be performed on blood by PCR?

A: HSV DNA is rarely detectable in blood of immunocompetent individuals, so blood PCR is not a routine screening tool. It is mainly used in specific situations such as suspected disseminated neonatal disease or severe infection in immunocompromised patients, on the advice of a clinician.

Q: How does HSV testing affect pregnancy management?

A: Identifying HSV infection status helps clinicians plan monitoring near term, decide on suppressive antiviral therapy, and determine whether cesarean delivery is indicated when lesions or prodromal symptoms are present at labor, thereby reducing neonatal herpes risk.